Dallah posts 38% rise in H1 profit

25/07/2017 Argaam Exclusive

View other reports

 

Dallah Healthcare Holding Co. reported a net profit of SAR 155 million for the first half of 2017, jumping 38 percent year-on-year (YoY), driven by lower G&A expenses and decreased Zakat. In addition, there was some impairment in intangible assets in the same quarter of last year which were not repeated this year.



Financials (M)

Item 6m 2016 6m 2017 Change‬
Revenues 573.38 590.95 3.1 %
Gross Income 262.31 274.08 4.5 %
Operating Income 121.24 156.67 29.2 %
Net Income 112.20 155.03 38.2 %
Average Shares 90.00 90.00 -
EPS (Riyals) 1.25 1.72 38.2 %

The company’s net profit for the second quarter increased 29.3 percent YoY to SAR 70 million on increase in number of medical procedures, higher operating efficiency and cost-saving policy.

 

On a quarterly basis, Q2 net profit fell 17.6 percent on seasonality factors, as the holy month of Ramadan and Eid Al Fitr fell in Q2. 



Current Quarter Comparison (M)

Compared With The
Item Q2 2016 Q2 2017 Change‬
Revenues 288.35 288.20 0.0 %
Gross Income 129.78 130.48 0.5 %
Operating Income 59.34 70.86 19.4 %
Net Income 54.14 69.99 29.3 %
Average Shares 90.00 90.00 -
EPS (Riyals) 0.60 0.78 29.3 %


Financial results (Million)

Period Revenues Change Gross Income Change Net Income Change EPS(Riyal)
Q1 2008 - - - - - - -
Q2 2008 - - - - - - -
Q3 2008 - - - - - - -
Q4 2008 - - - - - - -
Q1 2009 - - - - - - -
Q2 2009 - - - - - - -
Q3 2009 - - - - - - -
Q4 2009 - - - - - - -
Q1 2010 - - - - - - -
Q2 2010 - - - - - - -
Q3 2010 104.78 - 36.90 - 17.82 - 0.20
Q4 2010 120.09 - 39.97 - 24.33 - 0.27
Q1 2011 129.97 - 49.69 - 35.25 - 0.39
Q2 2011 139.34 - 50.86 - 27.14 - 0.30
Q3 2011 115.44 10.2 % 37.37 1.3 % 15.49 (13.1 %) 0.17
Q4 2011 142.59 18.7 % 51.97 30.0 % 35.53 46.0 % 0.39
Q1 2012 154.04 18.5 % 72.82 46.5 % 37.96 7.7 % 0.42
Q2 2012 161.32 15.8 % 73.73 45.0 % 37.09 36.7 % 0.41
Q3 2012 142.26 23.2 % 59.00 57.9 % 23.94 54.5 % 0.27
Q4 2012 179.43 25.8 % 81.51 56.9 % 34.37 (3.3 %) 0.38
Q1 2013 183.73 19.3 % 84.40 15.9 % 39.04 2.8 % 0.43
Q2 2013 187.79 16.4 % 80.68 9.4 % 23.64 (36.3 %) 0.26
Q3 2013 167.08 17.4 % 66.67 13.0 % 21.84 (8.7 %) 0.24
Q4 2013 211.05 17.6 % 95.71 17.4 % 52.11 51.6 % 0.58
Q1 2014 207.57 13.0 % 87.60 3.8 % 40.50 3.7 % 0.45
Q2 2014 219.45 16.9 % 93.78 16.2 % 34.33 45.2 % 0.38
Q3 2014 192.79 15.4 % 75.36 13.0 % 21.94 0.5 % 0.24
Q4 2014 240.08 13.8 % 103.54 8.2 % 50.35 (3.4 %) 0.56
Q1 2015 240.40 15.8 % 102.13 16.6 % 47.82 18.1 % 0.53
Q2 2015 245.23 11.7 % 100.89 7.6 % 35.86 4.4 % 0.40
Q3 2015 223.93 16.2 % 87.92 16.7 % 26.78 22.1 % 0.30
Q4 2015 276.50 15.2 % 116.81 12.8 % 54.60 8.4 % 0.61
Q1 2016 285.03 18.6 % 132.53 29.8 % 58.07 21.4 % 0.65
Q2 2016 288.35 17.6 % 129.78 28.6 % 54.14 51.0 % 0.60
Q3 2016 273.17 22.0 % 122.38 39.2 % 60.80 127.0 % 0.68
Q4 2016 316.24 14.4 % 151.01 29.3 % 51.71 (5.3 %) 0.57
Q1 2017 302.75 6.2 % 143.60 8.4 % 85.05 46.5 % 0.94
Q2 2017 288.20 0.0 % 130.48 0.5 % 69.99 29.3 % 0.78

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2008 - - -
Q2 2008 - - -
Q3 2008 - - -
Q4 2008 - - -
Q1 2009 - - -
Q2 2009 - - -
Q3 2009 - - -
Q4 2009 - - -
Q1 2010 - - -
Q2 2010 - - -
Q3 2010 - - -
Q4 2010 - - -
Q1 2011 - - -
Q2 2011 35.90 % 22.84 % 21.15 %
Q3 2011 35.24 % 22.42 % 20.24 %
Q4 2011 36.01 % 24.05 % 22.15 %
Q1 2012 38.63 % 24.79 % 21.67 %
Q2 2012 41.14 % 25.88 % 22.58 %
Q3 2012 42.90 % 25.84 % 22.97 %
Q4 2012 45.06 % 25.05 % 20.93 %
Q1 2013 44.79 % 24.18 % 20.16 %
Q2 2013 44.08 % 22.36 % 17.45 %
Q3 2013 43.63 % 21.80 % 16.56 %
Q4 2013 43.68 % 23.30 % 18.23 %
Q1 2014 42.75 % 23.14 % 17.85 %
Q2 2014 42.69 % 22.94 % 18.48 %
Q3 2014 42.42 % 22.43 % 17.92 %
Q4 2014 41.90 % 22.11 % 17.11 %
Q1 2015 41.98 % 21.38 % 15.76 %
Q2 2015 41.58 % 21.72 % 15.48 %
Q3 2015 41.54 % 21.77 % 15.49 %
Q4 2015 41.35 % 21.81 % 15.34 %
Q1 2016 42.51 % 23.29 % 17.20 %
Q2 2016 43.49 % 24.24 % 18.50 %
Q3 2016 44.66 % 25.57 % 19.88 %
Q4 2016 46.07 % 24.94 % 19.47 %
Q1 2017 46.32 % 26.38 % 21.29 %
Q2 2017 46.38 % 27.68 % 22.38 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2008 - - - -
Q2 2008 - - - -
Q3 2008 - - - -
Q4 2008 - - - -
Q1 2009 - - - -
Q2 2009 - - - -
Q3 2009 - - - -
Q4 2009 - - - -
Q1 2010 - - - -
Q2 2010 - - - -
Q3 2010 90.00 - - 3.67
Q4 2010 90.00 - - 3.94
Q1 2011 90.00 - - 4.29
Q2 2011 90.00 1.16 1.16 4.63
Q3 2011 90.00 1.14 1.14 4.80
Q4 2011 90.00 1.26 1.30 5.21
Q1 2012 90.00 1.29 1.33 5.66
Q2 2012 90.00 1.40 1.44 6.04
Q3 2012 90.00 1.49 1.53 6.31
Q4 2012 90.00 1.48 1.48 12.40
Q1 2013 90.00 1.49 1.49 12.83
Q2 2013 90.00 1.34 1.34 12.37
Q3 2013 90.00 1.32 1.32 12.64
Q4 2013 90.00 1.52 1.52 13.22
Q1 2014 90.00 1.53 1.53 13.75
Q2 2014 90.00 1.65 1.65 13.36
Q3 2014 90.00 1.65 1.65 13.65
Q4 2014 90.00 1.63 1.63 14.15
Q1 2015 90.00 1.72 1.56 14.74
Q2 2015 90.00 1.73 1.58 14.63
Q3 2015 90.00 1.79 1.63 14.86
Q4 2015 90.00 1.83 1.68 15.48
Q1 2016 90.00 1.95 1.97 16.15
Q2 2016 90.00 2.15 2.21 15.76
Q3 2016 90.00 2.53 2.48 16.26
Q4 2016 90.00 2.50 2.52 16.85
Q1 2017 90.00 2.80 2.79 17.78
Q2 2017 90.00 2.97 2.93 17.24

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2008 - - -
Q2 2008 - - -
Q3 2008 - - -
Q4 2008 - - -
Q1 2009 - - -
Q2 2009 - - -
Q3 2009 - - -
Q4 2009 - - -
Q1 2010 - - -
Q2 2010 - - -
Q3 2010 - - -
Q4 2010 - - -
Q1 2011 - - -
Q2 2011 - - -
Q3 2011 - - -
Q4 2011 - - -
Q1 2012 - - -
Q2 2012 - - -
Q3 2012 - - -
Q4 2012 25.26 25.26 3.02
Q1 2013 23.15 23.15 2.70
Q2 2013 26.26 26.26 2.85
Q3 2013 26.93 26.93 2.82
Q4 2013 26.15 26.15 3.00
Q1 2014 33.02 33.02 3.69
Q2 2014 33.91 33.91 4.19
Q3 2014 43.67 43.67 5.29
Q4 2014 45.25 45.25 5.23
Q1 2015 40.15 44.08 4.67
Q2 2015 45.84 50.27 5.43
Q3 2015 32.29 35.31 3.88
Q4 2015 27.26 29.73 3.23
Q1 2016 27.46 27.14 3.31
Q2 2016 28.54 27.81 3.89
Q3 2016 21.29 21.71 3.31
Q4 2016 27.05 26.85 4.01
Q1 2017 25.95 25.99 4.08
Q2 2017 26.81 27.16 4.62

Business Segments (Million)

Compared With The
Period Medical Services Medicine and Pharmaceutical Products
Q1 2011 118.62 11.35
Q2 2011 132.76 6.58
Q3 2011 110.16 5.99
Q4 2011 134.16 7.73
Q1 2012 141.87 12.17
Q2 2012 148.75 12.57
Q3 2012 133.35 8.91
Q4 2012 163.03 16.20
Q1 2013 169.97 13.76
Q2 2013 168.24 19.56
Q3 2013 158.17 8.92
Q4 2013 192.80 18.25
Q1 2014 195.44 12.12
Q2 2014 201.76 17.69
Q3 2014 177.26 15.52
Q4 2014 223.36 16.72
Q1 2015 224.02 16.38
Q2 2015 228.38 16.85
Q3 2015 215.41 8.52
Q4 2015 257.40 18.49
Q1 2016 276.15 8.88
Q2 2016 277.42 10.93
Q3 2016 265.04 8.13
Q4 2016 307.51 8.73
Q1 2017 239.94 62.81
Q2 2017 229.31 58.90

Analysts Estimates (Million)

Item Q2 2017 (e) Q2 2017 (a) Change‬
Average 65.93 69.99 6.15 %

Estimates vs Actual (Million)

Item Q2 2017 (e) Q2 2017 (a) Change
Al Rajhi Capital 68.00 69.99 2.9 %
Albilad Capital 67.00 69.99 4.5 %
AlJazira Capital 66.50 69.99 5.2 %
Arbah Capital 66.00 69.99 6.0 %
Hermes 65.00 69.99 7.7 %
HSBC 65.00 69.99 7.7 %
Sico 64.00 69.99 9.4 %

Current
Market Cap (M Riyal) 15,316.22
Enterprise Value (EV) (M) 17,219.70
Shares Outstanding ((M)) 97.68
EPS ( Riyal) (TTM) 3.94
Book Value (BV) ( Riyal) 34.02
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 39.80
P/E (TTM) 39.80
Price/book 4.61
Return on Average Assets (%) (TTM) 6.2
Return on Average Equity (%) (TTM) 11.9

Share Price

156.80
1.60 1.03 %

Dallah Healthcare Co. (DALLAH HEALTH)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.